Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma

Journal of Clinical Oncology

Volumn 25, Issue 19, 2007, Pages 2764-2769

  Ansell, Stephen M ^a   Horwitz, Steven M ^a   Engert, Andreas ^a   Khan, Khuda Dad ^a   Lin, Thomas ^a   Strair, Roger ^a   Keler, Tibor ^a   Graziano, Robert ^a   Blanset, Diann ^a   Yellin, Michael ^a   Fischkoff, Steven ^a   Assad, Albert ^a   Borchmann, Peter ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MDX 060; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD30; UNCLASSIFIED DRUG; CD30 ANTIGEN;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG TOLERANCE; DYSPNEA; EPISTAXIS; FEMALE; GRAFT VERSUS HOST REACTION; HEART TAMPONADE; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; T CELL LYMPHOMA; ADOLESCENT; COHORT ANALYSIS; DOSE RESPONSE; HISTIOCYTIC LYMPHOMA; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD30; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOTHERAPY; LYMPHOMA, LARGE-CELL; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 34447573999     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.07.8972     Document Type: Article

References (25)

1. Horie R, Watanabe T: CD30: Expression and function in health and disease. Semin Immunol 10:457-470, 1998
2. Tarkowski M: Expression and a role of CD30 in regulation of T-cell activity. Curr Opin Hematol 10:267-271, 2003
3. Hecht TT, Longo DL, Cossman J, et al: Production and characterization of a monoclonal antibody that binds Reed-Sternberg cells. J Immunol 134:4231-4236, 1985
4. Younes A, Carbone A: CD30/CD30 ligand and CD40/CD40 ligand in malignant lymphoid disorders. Int J Biol Markers 14:135-143, 1999
5. Pizzoto G, Vinanten F, Chilosi M, et al: CD30 antigen and cellular biology of Reed-Sternberg cells. Blood 84:3983-3984, 1994
6. Opat S, Gaston JS: CD30: CD30 ligand interactions in the immune response. Autoimmunity 33:45-60, 2000
7. Staudt LM: The molecular and cellular origins of Hodgkin's disease. J Exp Med 191:207-212, 2000
8. Hinz M, Lemke P, Anagnostopoulos I, et al: Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. J Exp Med 196:605-617, 2002
9. Pinto A, Aldinucci D, Gloghini A, et al: Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin's disease cell line. Blood 88:3299-3305, 1996
10. Molin D, Fischer M, Xiang Z, et al: Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease. Br J Haematol 114:616-623, 2001
11. Borchmann P, Treml JF, Hansen H, et al: The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma. Blood 102:3737-3742, 2003
12. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI-Sponsored International Working Group. J Clin Oncol 17:1244-1253, 1999
13. Ansell SM, Armitage JO: Management of Hodgkin lymphoma. Mayo Clin Proc 81:419-426, 2006
14. Stein H, Foss HD, Durkop H, et al: CD30(+) anaplastic large cell lymphoma: A review of its histopathologic, genetic, and clinical features. Blood 96:3681-3695, 2000
15. Horning S, Chao N, Negrin R, et al: High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices. Blood 89:801-813, 1997
16. Moskowitz C, Nimer S, Zelenetz A, et al: A 2-step comprehensive high-dose chemoradiotherapy second line program for relapsed and refractory Hodgkin's disease: Analysis by intent to treat and development of a prognostic model. Blood 97:616-623, 2001
17. Hartmann F, Renner C, Jung W, et al: Anti-CD16/CD30 bispecific antibodies as possible treatment for refractory Hodgkin's disease. Leuk Lymphoma 31:385-392, 1998
18. Falini B, Bolognesi A, Flenghi L, et al: Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. Lancet 339:1195-1196, 1992
19. Schnell R, Staak O, Borchmann P, et al: A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. Clin Cancer Res 8:1779-1786, 2002
20. Borchmann P, Schnell R, Fuss I, et al: Phase 1 trial of the novel bispecific molecule H22XKi-4 in patients with refractory Hodgkin lymphoma. Blood 100:3101-3107, 2002
21. Schnell R, Dietlein M, Staak JO, et al: Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. J Clin Oncol 23:4669-4678, 2005
22. Leonard J, Rosenblatt J, Bartlett N, et al: Phase II study of SGN-30 (anti-CD30 monoclonal antibody) in patients with relapsed or recurrent Hodgkin's disease. Blood 104:2635a, 2004
23. Forero-Torres A, Bernstein SH, Gopal A, et al: SGN-30 (anti-CD30 mAb) has a single-agent response rate of 21% in patients with refractory or recurrent systemic anaplastic large cell lymphoma (ALCL). Blood 108:768a, 2006
24. Hueck F, Ellermann J, Borchmann P, et al: Combinations of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell lines. J Immunother 27:347-353, 2004
25. Boll B, Hansen H, Heuck F, et al: The fully human anti-CD30 antibody 5F11 activates NF-kappaB and sensitizes lymphoma cells to bortezomib-induced apoptosis. Blood 106:1839-1842, 2005